Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease

The requested reference [85282f1321120f8562e40ab385eeb2404f7d9324] no longer exists in our database. It has been replaced by the current reference: [a9e93e05cbf444312bf93d3723dff0cf1b846018]

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to treat idiopathic multicenter Castleman disease (iMCD).
Epistemonikos ID: 6c8910fd07531719dfbf2ee0f6208a25c632eab6
First added on: Oct 14, 2026